MedTrace Logo

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

NCT06846736 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-02-26

No results posted yet for this study

Summary

The Goal of this observational study is to develop an AI-driven pathologic image analysis-based classifier that can identify patients unlikely to significantly benefit from the currently utilized first-line ALK inhibitors (advanced-generation ALK inhibitors). Our goal is a classifier with final ROC-AUC value of 0.75.

Conditions

  • Alk-positive Non-Small Cell Lung Cancer
  • ALK-inhibitor Treated

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Gustave Roussy, Cancer Campus, Grand Paris

    collaborator OTHER

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Jair Bar, MD-PhD · Sheba Medical Cernter

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-13
Primary Completion
2027-12-01
Completion
2028-12-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06846736 on ClinicalTrials.gov